외음부암 시장 규모, 점유율 및 성장 분석 : 암 유형별, 치료법별, 최종 사용자별 및 지역별 예측(2026-2033년)

Global Vulvar Cancer Market size was valued at USD 595.3 million in 2024 and is poised to grow from USD 652.45 million in 2025 to USD 1358.41 million by 2033, growing at a CAGR of 9.6% during the forecast period (2026-2033).

The global vulvar cancer market is experiencing significant growth driven by increasing incidence rates, especially among aging populations and those affected by HPV. The emergence of new targeted therapies, immuno-oncology drugs, and advanced diagnostic technologies, including AI-guided biopsies, is catalyzing market expansion. Heightened awareness campaigns and government initiatives aimed at enhancing cancer treatment are further propelling growth by improving access to early diagnosis and care worldwide. Noteworthy advancements in immunotherapy have transformed treatment landscapes, underlined by extensive research focused on HPV-related cancers, which underscores the critical role of targeted interventions in shaping future therapeutic options and driving industry growth. This evolving landscape presents substantial opportunities for stakeholders within the vulvar cancer market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Vulvar Cancer market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Vulvar Cancer Market Segments Analysis

Global Vulvar Cancer Market is segmented by Cancer Type, Treatment Type, End Users and region. Based on Cancer Type, the market is segmented into Vulvar Squamous Cell Carcinoma, Vulvar Melanoma, Adenocarcinoma and Basal Cell Carcinoma. Based on Treatment Type, the market is segmented into Chemotherapy, Surgery, Laser Surgery, Excision, Skinning Vulvectomy, Radical Vulvectomy, Radiation Therapy and Biologic Therapy. Based on End Users, the market is segmented into Hospitals and Clinics, Research and Academic Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Vulvar Cancer Market

One key market driver for the global vulvar cancer market is the increasing awareness and early detection of gynecological cancers among women. Enhanced educational initiatives and the dissemination of information regarding vulvar cancer symptoms and risks have led to more women seeking medical consultations and screenings. This heightened awareness not only contributes to earlier diagnosis but also fosters a greater demand for treatment options, including medical therapies, surgical interventions, and supportive care. Additionally, improvements in healthcare access and advancements in diagnostic technologies are further propelling the growth of the vulvar cancer market, creating a more robust landscape for innovative treatment solutions.

Restraints in the Global Vulvar Cancer Market

One significant market restraint for the global vulvar cancer market is the lack of awareness and understanding about the disease among the general population as well as healthcare professionals. Vulvar cancer is relatively rare, leading to limited research funding and fewer treatment options compared to more prevalent cancers. This lack of awareness often results in delayed diagnosis and treatment, adversely affecting patient outcomes. Additionally, cultural stigmas surrounding discussions of female reproductive health further hinder education efforts and may discourage women from seeking medical help for symptoms, ultimately restricting the overall market growth for vulvar cancer diagnostics and therapies.

Market Trends of the Global Vulvar Cancer Market

The global vulvar cancer market is witnessing a significant shift driven by the accelerated adoption of immunotherapy, particularly immune checkpoint inhibitors. This therapeutic approach harnesses the body's immune system to accurately identify and combat cancer cells, offering new hope for patients with advanced vulvar cancer. As clinical trials demonstrate promising results, healthcare providers increasingly prioritize immunotherapy protocols over traditional treatments, reshaping patient management strategies. The growing awareness of vulvar cancer and advancements in targeted therapies are further propelling market dynamics, suggesting a robust future for innovative treatment solutions that enhance patient outcomes and quality of life.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Technology Assessment

Global Vulvar Cancer Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Vulvar Squamous Cell Carcinoma
• Vulvar Melanoma
• Adenocarcinoma
• Basal Cell Carcinoma

Global Vulvar Cancer Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Chemotherapy
• Surgery
• Laser Surgery
• Excision
• Skinning Vulvectomy
• Radical Vulvectomy
• Radiation Therapy
• Biologic Therapy

Global Vulvar Cancer Market Size by End Users & CAGR (2026-2033)

• Market Overview
• Hospitals and Clinics
• Research and Academic Institutes
• Others

Global Vulvar Cancer Market Size & CAGR (2026-2033)

• North America (Cancer Type, Treatment Type, End Users)
  • US
  • Canada
• Europe (Cancer Type, Treatment Type, End Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Cancer Type, Treatment Type, End Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Cancer Type, Treatment Type, End Users)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Cancer Type, Treatment Type, End Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Merck & Co., Inc. (MSD)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (GSK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (BMS)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inovio Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Bovax Biotechnology Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Xencor, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Transgene SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GI Innovation, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TScan Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Marengo Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SCG Cell Therapy Pte. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HRYZ Biotech Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chimerix
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Companya
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations